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This retrospective report compared the 4-year outcomes of allogeneic stem cell transplantation (allo-SCT) in
651 adult patients with acute myeloid leukemia receiving a reduced-intensity (RIC) or nonmyeloablative
conditioning (NMA) regimen according to the type of unrelated donors. These were either umbilical cord
blood (UCB, n ¼ 205), a 9/10 mismatched unrelated donor (MisMUD, n ¼ 99), or a 10/10 matched unrelated
donor (MUD, n ¼ 347) graft. Neutrophil recovery was slower in UCB (74.5% by day 42) compared with
MisMUD (94.8%) and MUD (95.6%) (P < .001). There was no signiﬁcant difference in nonrelapse mortality
between UCB and both MUD (hazard ratio [HR], 1.05; 95% conﬁdence interval [CI], .62 to 1.78; P ¼ .85) and
MisMUD (HR, 1.58; 95% CI, .88 to 2.83; P ¼ .13) The relapse/progression was similar between UCB and Mis-
MUD (HR, .62; 95% CI, .37 to 1.03; P ¼ .07), but was signiﬁcantly lower in MUD compared with UCB (HR, .60;
95% CI, .39 to .92; P ¼ .02). The rate of extensive chronic graft-versus-host disease (GVHD) was similar be-
tween UCB and both MUD (HR, 2.15; 95% CI, .93 to 4.97; P ¼ .08) and MisMUD (HR, 1.84; 95% CI, .68 to 4.95;
P ¼ .23). The rate of severe grade III and IV acute GVHD was signiﬁcantly increased in MisMUD compared with
UCB (HR, 2.61; 95% CI, 1.30 to 5.23; P ¼ .007). There was no signiﬁcant difference in overall survival between
UCB and both MisMUD (HR, .98; 95% CI, .66 to 1.45; P ¼ .92) and MUD (HR, .74; 95% CI, .52 to 1.03; P ¼ .08).
These data suggest that in the setting of RIC/NMA, allo-SCT UCB is a valid alternative graft source, with
signiﬁcantly less chronic GVHD, compared with MisMUD, when there is no MUD available or when urgent
transplantation is needed.
 2015 American Society for Blood and Marrow Transplantation.dgments on page 1065.
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Allogeneic stem cell transplantation (allo-SCT) is a well-
established therapy for the treatment of acute myeloid leu-
kemia (AML) in adult patients. Although HLA-matched
F. Malard et al. / Biol Blood Marrow Transplant 21 (2015) 1059e10671060sibling donor (MSD) is the preferred donor, only about 30% of
patients have such a donor available. The lack of MSD leads
transplantation centers to search for alternative donors,
which now account for more than one half of trans-
plantations performed [1,2]. Currently, for AML patients who
lack anMSD but require allo-SCT, the choice will primarily be
an HLA-matched unrelated donor (MUD). However, the
likelihood of identifying a MUD is, at most, 75% and it could
be much lower depending of the patient’s ethnic origin [3].
Therefore, umbilical cord blood (UCB) and mismatched un-
related donor (MisMUD) have emerged as effective stem cell
sources for allo-SCT candidates who cannot beneﬁt from an
MSD or a MUD. Several studies found a comparable
leukemia-free survival between UCB, HLA 8/8 MUD, and HLA
7/8 MisMUD in the setting of myeloablative conditioning
(MAC) [4,5], reduced-intensity conditioning (RIC), and non-
myeloablative (NMA) regimens [6]. One study evaluating
alternative donors was limited to elderly AML patients in
ﬁrst complete remission [7]. However, in spite of the patient
population comprising only those over the age of 50, both
MAC and RIC/NMA regimens were included [7]. MAC regi-
mens are limited to younger patients and to patients in good
medical condition because of the high incidence of non-
relapse mortality (NRM) [8]. RIC/NMA regimens have been
developed in an attempt to decrease NRM in elderly patients,
in heavily pretreated patients, or in those with medical
comorbidities precluding the use of standard MAC regimens
[9,10]. RIC and NMA regimens aim to take advantage of the
graft-versus-leukemia effect mediated by the donor’s
immunocompetent cells rather than the upfront cytoreduc-
tive effect of the conditioning chemotherapy [11]. Evaluating
the effect of alternative donors in patients who received a
RIC/NMA regimen seems more relevant than only in patients
over age 50, whatever their conditioning.
Furthermore, in many non-European centers, HLA
matching was performed at the HLA-A, -B, -C, and -DRB1
high-resolution level (8/8 HLA matching) whereas, in many
European centers, unrelated donor choice includes also HLA-
DQB1 (10/10 HLA matching) for unrelated donors, as similar
outcomes between MUD and 10/10 HLA MUD were reported
[12].
Taking all this into consideration, the aim of our study
was to evaluate outcomes of AML adult patients after 10/10
HLA MUD peripheral blood stem cell (PBSC), HLA 9/10 Mis-
MUD PBSC, and UCB allo-SCT in the RIC/NMA setting.
PATIENTS AND METHODS
Study Design
This was a retrospective and multicenter study of the Société Française
de Greffe de Moelle et de Therapie Cellulaire (participating centers listed in
Supplemental Data). For the purpose of this analysis, all patients diagnosed
with AML (except acute promyelocytic leukemia) who were at least 18 years
of age at the time of transplantation, and who received a granulocyte
colonyestimulating factoremobilized PBSC MUD (MUD group), a gran-
ulocyte colonyestimulating factoremobilized PBSC 1 allele or antigen-
mismatched unrelated donor (MisMUD group), or 1 or 2 UCB (UCB group)
transplantation after a RIC or a NMA conditioning were included. These
included 651 patients who underwent transplantation between April 2002
and December 2010. There were 99 patients in the MisMUD, 205 in the UCB,
and 347 in the MUD groups. Patients without a suitable HLA 10/10-matched
related or unrelated donor were considered for a 9/10 MisMUD. However, if
therewas no sufﬁcient time for an unrelated donor search because of a high-
risk disease, or if the preliminary search indicated a lower likelihood of
ﬁnding an unrelated donor within a reasonable time frame, the use of UCB
was preferred.
The eligibility criteria for RIC or NMA allo-SCT included the following:
(1) patients above age 50, (2) heavily pretreated patients who received an
autologous stem cell transplant (auto-SCT) or more than 2 lines of chemo-
therapy before allo-SCT, and (3) patients with poor performance statusbecause of signiﬁcant medical comorbidities as described by Sorror et al. [8].
Written informed consent was obtained from each patient and donor. For
the purpose of this study, patients who received a MAC regimen were
excluded [13]; all patients received either a RIC or a NMA regimen. The
following regimens were considered as NMA [13]: low-dose (2 Gy) total
body irradiation (TBI), ﬂudarabine (Flu) and cyclophosphamide (Cy); 2 Gy
TBI and Flu; Flu and Cy; low-dose busulfan (3.2 mg/kg) and Flu. All other
regimens were considered RIC regimens.
Transplantation Procedures
All donor-recipient pairs were typed at the allelic level. They were ﬁrst
typed at the 2-digit level for HLA class I (HLA-A, HLA-B, and HLA-C) and class
II (HLA-DRB1 and HLA-DQB1) using published HLA class I PCR sequence-
speciﬁc oligonucleotide and/or PCR sequence-speciﬁc primers typing
protocols. Per study deﬁnition, all donor-recipient pairs were matched at
HLA-A, -B, -C, -DRB1, and -DQB1 at the allele level (10/10 matched) in the
MUD group, and in the MisMUD group, all donor/recipient pairs presented a
single HLA mismatch (9/10 matched). Such mismatch was at HLA-A for 24
patients (24%), HLA-B for 16 patients (16%), HLA-C for 36 patients (37%), and
HLA-DQB1 for 23 patients (23%), with no donor-recipient pair presenting a
mismatch at HLA-DRB1 (Table 1). HLA-DP typing was not routinely per-
formed during the study period. HLA typing was performed according to the
current protocol of the European Federation for Immunogenetics Histo-
compatibility Laboratory standards. HLA typing in UCB recipients was per-
formed at antigen level for HLA class I A and B loci and at allelic level with
high-resolution typing for HLA class II DRB1 locus. Matching at HLA-C or
allele level for HLA-A and -B were not considered, as these data were not
available at the time analysis. The majority (n ¼ 178; 87%) of UCB donor-
recipient pairs were mismatched at 1 or 2 HLA loci, 12 (6%) presented a
mismatched at 3 HLA loci, 6 (3%) presented no HLA mismatch, and in 9 (4%),
the donor-recipient HLA mismatch was unknown. Of the 205 patients who
received UCB grafts, 99 (48%) received 1 UCB unit and 106 (52%) received 2
units. We decided to group together UCB transplantation using 1 or 2 UCB
units, as no signiﬁcant differences in survival are reported between the 2
[14,15]. Furthermore, univariate analysis was performed to compare patient
outcomes after single and double UCB in our cohort: there was no difference
in term of overall survival (OS), progression-free survival (PFS), NRM,
relapse/progression, acute and chronic graft-versus-host disease (GVHD)
(data not shown). HLA match between UCB units (n ¼ 106) was not
considered. All patients received the preparative regimen as inpatients in
single rooms and remained hospitalized until hematopoietic and clinical
recovery. Supportive care and antimicrobial prophylaxis were left to the
initiative of the centers [16,17]. All blood products were ﬁltered, irradiated,
and screened for cytomegalovirus (CMV). In the ﬁrst 100 days after allo-SCT,
patients were assessed at least once per week for CMV infection to initiate
preemptive therapy. For GVHD prophylaxis, most patients received either
cyclosporine A (CsA) alone or in combination with methotrexate or myco-
phenolate mofetil (MMF). CsAwas administered at a dose of 3 mg/kg/day by
continuous intravenous infusion starting from day -3 or -2, and changed to
twice daily oral dosing as soon as tolerated [18]. Methotrexate was admin-
istered as a short course (15 mg/m2 at day þ1, 10 mg/m2 at day þ3 and þ6).
MMFwas given at a ﬁxed oral dose of 2 g/day. No treatment adjustment was
performed for MMF. MMF was tapered over 4 weeks starting from day 60,
and CsA from day 90 if no GVHD appeared.
Outcomes
Recorded clinical outcomes after transplantation included time to
neutrophil and platelet engraftment, time of onset and severity of acute
GVHD (aGVHD), chronic GVHD (cGVHD), disease relapse or progression, PFS,
and OS. Time to neutrophil recovery was deﬁned as the ﬁrst of 3 consecutive
days inwhich the absolute neutrophil count exceeded .5109/L, and time to
platelet recovery as the ﬁrst of 3 days with 50  109/L or higher without a
need for platelet transfusion during a 5-day period. Acute and chronic GVHD
were evaluated according to standard criteria [19,20], as data to determine
National Institutes of Health cGVHD classiﬁcation were not available for
most patients. NRM was deﬁned as death occurring in the absence of leu-
kemia relapse. OS was the primary endpoint. Secondary endpoints included
overall PFS, relapse rate, NRM, aGVHD and cGVHD, and engraftment.
Statistical Methods
OS and PFS were calculated by the Kaplan-Meier method and subgroups
were compared using the log-rank test. For categorical variables, compari-
son between the MisMUD, the MUD, and the UCB groups was carried out
using the chi-squared test. For continuous data, comparison between regi-
mens was performed using the Mann-Whitney test. Probabilities of relapse/
progression, NRM, GVHD, and neutrophil and platelet recovery were
calculated using the cumulative incidence procedure and comparisons were
performed using the Gray test. Univariate analysis was performed to
Table 1
Study Population and Transplantation Characteristics
Characteristic UCB (n ¼ 205) MisMUD (n ¼ 99) MUD (n ¼ 347) P Value
Patient age, median (range), yr 49.0 (19.3-69.1) 55.1 (19.0-68.2) 57.1 (19.0-70.3) <.001
Gender (female) 117 (57.1%) 56 (57.0%) 166 (47.8%) .07
CMV-seronegative donor-recipient pair 44 (21.5%) 21 (21.0%) 120 (34.6%) <.001
Disease status <.001
CR1 100 (48.8%) 47 (48.0%) 193 (57.1%)
CR > 1 83 (40.5%) 30 (30.0%) 92 (26.5%)
Relapse/progression 22 (10.7%) 22 (22.0%) 57 (16.4%)
Cytogenetic risk .31
Low 14 (6.8%) 5 (5.0%) 28 (8.1%)
Intermediate 115 (56.1%) 63 (64.0%) 225 (64.8%)
High 42 (20.5%) 16 (16.0%) 54 (15.6%)
Unknown 34 (16.6%) 15 (15.0%) 40 (11.5%)
Stem cell source NA
PBSC - 99 347
1 UCB 99 (48.3%) - -
2 UCB 106 (51.7%) - -
HLA matching: 1 UCB
6/6 4 (2.0%) - -
6/5 26 (12.7%) - -
4/6 61 (29.8%) - -
3/6 6 (2.9%) - -
Missing data 2 (1.0%) - -
HLA matching: dUCB NA
6/6 þ 6/6 2 (1.0%) - -
6/6 þ 5/6 6 (2.9%) - -
6/6 þ 4/6 2 (1.0%) - -
5/6 þ 5/6 20 (9.8%) - -
5/6 þ 4/6 23 (11.2%) - -
4/6 þ 4/6 40 (19.5%) - -
4/6 þ 3/6 5 (2.4%) - -
3/6 þ 3/6 1 (.5%) - -
Missing data 7 (3.4%) - -
HLA matching: 9/10 NA
Mismatch at HLA-A - 24 (24.0%) -
Mismatch at HLA-B - 16 (16.0%) -
Mismatch at HLA-C - 36 (37.0%) -
Mismatch at HLA-DRB1 - 0 (0%) -
Mismatch at HLA-DQB1 - 23 (23.0%) -
Cell dose, median (range)*
TNC 108/kg 0.31 (0.02-0.82) 8.70 (2.49-18.24) 8.48 (.05-19.23) <.001
CD34þ cells 106/kg 0.1 (.04-0.9) 5.71 (1.85-20.66) 6.40 (.20-21.4) <.001
Conditioning regimen <.001
NMA 179 (87.0%) 27 (27.0%) 108 (31.1%)
RIC 26 (13.0%) 72 (73.0%) 239 (68.9%)
TBI-based regimen <.001
Yes 194 (95.0%) 28 (28.0%) 83 (23.9%)
No 11 (5.0%) 71 (72.0%) 264 (76.1%)
ATG <.001
Yes 9 (4.0%) 80 (81.0%) 265 (76.4%)
No 196 (96.0%) 19 (19.0%) 82 (23.6%)
GVHD prophylaxis <.001
CsA þ MMF 160 (78.0%) 52 (53.0%) 178 (51.3%)
CsA þ MTX 2 (1.0%) 21 (21.0%) 49 (14.1%)
CsA 8 (3.9%) 18 (18.0%) 103 (29.7%)
Others 4 (2.0%) 6 (6.0%) 10 (2.9%)
Unknown 31 (15.1%) 2 (2.0%) 7 (2.0%)
Median follow-up, (range), mo 48.6 (12.0-97.8) 42.8 (18.7-104.9) 43.2 (12.1-126.7) .02
NA indicates not available; dUCB, double umbilical cord blood; TNC, total nucleated cells; MTX, methotrexate.
Data presented are n (%), unless otherwise indicated.
* For patients who received 2 UCB, the CD34 dose and TNC of each cord blood unit were added.
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younger than 40 years), sex of the donor, year of transplantation (2002 to
2006 versus 2007 to 2010), disease status at time of transplantation, cyto-
genetic status, conditioning regimen, use of TBI, use of antithymocyte
globulin (ATG), GVHD prophylaxis, and time between diagnosis and trans-
plantation. Also, these parameters were evaluated in a multivariate analysis
for outcome. The only covariate with missing data was cytogenetic status
(missing in 13.7% of patients) for which an “unknown” groupwas created. To
study the association between graft type and outcomes, multivariate Cox
regressions models were built. The variable for graft type as the main study
question was retained in all steps of model building. All P values are 2-sided
and values .05 were considered signiﬁcant. Datawere computed using theR package (R Foundation for Statistical Computing, Vienna, Austria) and
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
RESULTS
Patients and Transplantation Characteristics
Patients and transplantation characteristics for the whole
study population and for each group are detailed in Table 1.
Compared with PBSC recipients, UCB recipients were
younger. The median age at transplantation was 49 years in
the UCB group, compared with 55 years in the MisMUD and
F. Malard et al. / Biol Blood Marrow Transplant 21 (2015) 1059e1067106257 years in the MUD group. In the latter, fewer patients were
female and more donor-recipient pairs were CMV seroneg-
ative. Although the majority of patients underwent trans-
plantation in complete remission (CR) in all groups, there
were more patients in ﬁrst CR in the MUD group and fewer
patients in relapse or progression in the UCB group at the
time of transplantation. Whereas cytogenetic data were
available for the majority of patients (86.3%), molecular ge-
netic dataweremissing for many (36.6%) and, for this reason,
only cytogenetic data were considered to classify patients
according to the European Leukemia Net criteria [21].
Favorable risk cytogenetics was similar across the 3 groups,
ie, 6.8% in UCB, 5.0% in MisMUD, and 8.1% in MUD, but the
frequency of high cytogenetic risk was increased in the UCB
group: 20.5% versus 16% and 15.6% in the MisMUD and MUD
groups, respectively. The median numbers of total nucleated
and CD34þ cells were lower in the UCB group compared with
the MisMUD and the MUD groups. Whereas only 27.0% and
31.1% of patients received an NMA regimen in the MisMUD
and MUD groups, respectively, this type of conditioning was
used in the majority (87.0%) of patients in the UCB group.
This difference was due to the frequent use of the classical
NMA Flu, Cy, and 2 Gy TBI conditioning regimen in the UCB
setting [22]. Similarly, whereas TBI was applied to 95.0% of
patients in the UCB group, only 28.0% and 23.9% of patients
received TBI in the MisMUD and MUD groups, respectively.
Only 4.0% of patients who were not heavily pretreated in the
UCB group received ATG (Thymoglobulin; Genzyme, Lyon,
France), whereas 81.0% and 76.4% received ATG in the Mis-
MUD and the MUD groups, respectively, because of the ex-
pected higher risk of GVHD in these groups. The combination
of CsA and MMF was used in the majority of patients in all
groups for GVHD prophylaxis, but it wasmore frequent in the
UCB cohort. The median follow-up among surviving patients
was longer in the UCB group (48.6 months) than in the
MisMUD (42.8 months) and MUD (43.2 months) groups.Table 2
Transplantation-Related Events Univariate Analysis
Outcome UCB
(n ¼ 205)
MisMUD
(n ¼ 99
OS
At 2 Yr (95% CI) 47.9 (40.9-54.6) 50.5 (4
At 5 Yr (95% CI) 36.1 (28.7-43.5) 32.6 (2
PFS
At 2 Yr (95% CI) 42.0 (35.2-48.7) 49.5 (3
At 5 Yr (95% CI) 28.3 (21.2-35.8) 33.7 (2
NRM
At 2 Yr (cumulative incidence) 18.6% (15.9-21.3) 23.2% (1
At 5 Yr (cumulative incidence) 21.0% (17.9-24.1) 30.5% (2
Acute GVHD at days 100
Grade 2-4 32.2% (28.9-35.5) 39.4% (3
Grade 3-4 11.7% (9.4-14.0) 20.2% (1
Overall chronic GVHD
At 2 Yr (cumulative incidence) 16.1% (13.5-18.7) 29.3% (2
At 5 Yr (cumulative incidence) 16.6% (14.0-19.2) 30.5% (2
Extensive chronic GVHD
At 2 Yr (cumulative incidence) 5.8% (4.2-7.4) 10.1% (7
At 5 Yr (cumulative incidence) 5.8% (4.2-7.4) 10.1% (7
Relapse/progression
At 2 Yr (cumulative incidence) 39.6% (36.2-43.0) 27.3% (2
At 5 Yr (cumulative incidence) 50.8% (46.9-54.7) 35.7% (3
ANC > .5  109/L, median (range), d 19 (0-106) 15 (0
ANC > 500
At Day 28 (cumulative incidence) 72.8 (69.5-76.1) 94.8 (9
At Day 42 (cumulative incidence) 74.5 (70.9-78.1) 94.8 (9
Platelet > 50  109/L, median (range), d 41 (1-222) 13 (4
Platelet > 50  109/L at d 180
(cumulative incidence)
56.0 (52.2-59.8) 75.3 (7
ANC indicates absolute neutrophil count.Neutrophil and Platelet Recovery
Univariate analysis of transplantation-related events is
summarized in Table 2. Overall hematopoietic recovery was
signiﬁcantly slower in the UCB compared with the MisMUD
and the MUD groups. Median time to neutrophil recovery
was signiﬁcantly longer in the UCB group,19 (range, 0 to 106)
days, compared with 15 (range, 0 to 31) days in the MisMUD
and 16 (0 to 52) days in the MUD group (P < .001 for both).
The same was observed for median time to platelet recovery,
which was signiﬁcantly longer in the UCB group, 41 (range, 1
to 222) days compared with 13 (range, 4 to 73) days in the
MisMUD and 12 (range, 0 to 371) days in theMUD group (P<
.001 for both). The day 42 cumulative incidences of neutro-
phil recovery was signiﬁcantly lower in the UCB group, 74.5%
(95% conﬁdence interval [CI], 70.9% to 78.1%) compared with
94.8% (95% CI, 92.4% to 97.2%) in the MisMUD and 95.6% (95%
CI, 94.0% to 96.4%) in the MUD group (P < .001 for both)
(Figure 1A). The day 180 cumulative incidence of platelet
recovery was signiﬁcantly lower in the UCB group: 56.0%
(95% CI, 52.2% to 59.8%) versus 75.3% (95% CI, 70.7% to 79.9%)
in theMisMUD and 84.2% (95% CI, 82.1% to 86.3%) in theMUD
group (P < .001 for both) (Figure 1B).
GVHD and NRM
Multivariate analysis of transplantation-related events is
summarized in Table 3. The cumulative incidence of severe
grade III and IV aGVHDwas 11.7% in the UCB group compared
with 20.2% in the MisMUD (P ¼ .05) and 13.0% in the MUD
group (P ¼ .71) (Figure 2A). In multivariate analysis, the rate
of severe grade III and IV aGVHD was similar between UCB
and MUD groups (hazard ratio [HR], 1.72; 95% CI, .93 to 3.19;
P ¼ .08). However, the rate of severe grade III and IV aGVHD
was signiﬁcantly increased in the MisMUD group compared
with the UCB group (HR, 2.61; 95% CI, 1.30 to 5.23; P ¼ .007).
Graft type was the only parameter with a signiﬁcant impact
on grade III and IV aGVHD in multivariate analysis.)
MUD
(n ¼ 347)
P Value
(CB versus
MisMUD)
P Value
(CB versus MUD)
0.3-59.8) 56.7 (51.2-61.8) .81 .007
3.6-44.0) 48.6 (42.2-54.7)
9.3-58.9) 54.0 (48.6-59.1) .53 .001
3.3-44.4) 47.4 (41.5-53.0)
8.9-27.5) 16.6% (14.6-18.6) .08 .73
5.7-35.7) 20.5% (18.1-22.9)
4.5-44.3) 31.1% (28.6-33.6) .21 .73
6.1-24.3) 13.0% (11.2-14.8) .05 .71
4.7-33.9) 36.7% (34.1-39.3) .004 <.001
5.8-35.2) 39.1% (36.4-41.8)
.0-13.2) 11.5% (9.8-13.2) .18 .02
.0-13.2) 12.2% (10.4-14.0)
2.8-31.8) 29.6% (27.1-32.1) .03 .002
0.2-41.2) 32.2% (29.6-34.8)
-31) 16 (0-52) <.001 .001
2.4-97.2) 95.6 (94.0-96.4) <.001 <.001
2.4-97.2) 95.6 (94.0-96.4)
-73) 12 (0-371) <.001 <.001
0.7-79.9) 84.2 (82.1-86.3) <.001 <.001
Figure 1. Engraftment after allo-SCT in the MUD (green line), the MisMUD (blue line) and the UCB groups (red line). (A) Shows cumulative incidence of neutrophil
recovery to more than .5  109/L. (B) Shows cumulative incidence of platelet recovery to more than 50  109/L.
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was 5.8% in the UCB group,10.1% in theMisMUD (P¼ .18), and
11.5% in the MUD group (P ¼ .02) (Figure 2B). In multivariate
analysis, the rate of extensive cGVHD was similar between
UCB group and both the MUD (HR, 2.15; 95% CI, .93 to 4.97;
P ¼ .08) and the MisMUD group (HR, 1.84; 95% CI, .68 to 4.95;
P ¼ .23). No parameter, including the use of ATG, had a sig-
niﬁcant impact on extensive cGVHD in multivariate analysis.NRM, Relapse Incidence, PFS, and OS
At 2 years, the cumulative incidence of NRM was 18.6% in
the UCB group compared with 16.6% in the MUD group (P ¼
.73) and 23.2% in the MisMUD group (P ¼ .08) (Figure 3A). In
multivariate analysis, there was no signiﬁcant difference in
NRM between the UCB group and both the MUD (HR, 1.05;Table 3
Transplantation-Related Events Multivariate Analysis
Outcome HR
(95% CI)
P Value
OS
9/10 HLA-matched PBSC versus UCB .98 (.66-1.45) .92
10/10 HLA-matched PBSC versus UCB .74 (.52-1.03) .08
Relapse/progression versus CR 3.15 (2.40-4.14) <.001
Age > 40 yr versus < 40 yr 1.35 (1.02-1.79) .04
PFS
9/10 HLA-matched PBSC versus UCB 1.17 (.86-1.65) .29
10/10 HLA-matched PBSC versus UCB 1.10 (.84-1.42) .49
Relapse/progression versus CR 2.94 (2.26-3.83) <.001
Cytogenetic adverse versus favorable 2.67 (1.55-4.61) <.001
Cytogenetic Intermediate versus favorable 2.15 (1.29-3.59) .003
NRM
9/10 HLA-matched PBSC versus UCB 1.58 (.88-2.83) .13
10/10 HLA-matched PBSC versus UCB 1.05 (.62-1.78) .85
Relapse/progression versus CR 2.25 (1.41-3.58) <.001
Age > 40 yr versus < 40 yr 1.89 (1.10-3.24) .02
Relapse/progression
9/10 HLA-matched PBSC versus UCB .62 (.37-1.03) .07
10/10 HLA-matched PBSC versus UCB .60 (.39-.92) .02
Relapse/progression versus CR 3.64 (2.61-5.06) <.001
Cytogenetic adverse versus favorable 4.47 (2.02-9.85) <.001
Cytogenetic intermediate versus favorable 3.43 (1.60-7.36) .002
Grade III-IV acute GVHD
9/10 HLA-matched PBSC versus UCB 2.61 (1.30-5.23) .007
10/10 HLA-matched PBSC versus UCB 1.72 (.93-3.19) .08
Extensive chronic GVHD
9/10 HLA-matched PBSC versus UCB 1.84 (.68-4.95) .23
10/10 HLA-matched PBSC versus UCB 2.15 (.93-4.97) .0895% CI, .62 to 1.78; P ¼ .85) and the MisMUD group (HR, 1.58;
95% CI, .88 to 2.83; P ¼ .13). At 2 years, the cumulative inci-
dence of relapse/progressionwas 39.6% in the UCB group and
27.3% and 29.6% in the MisMUD and MUD groups, respec-
tively (P ¼ .03 and P ¼ .002) (Figure 3B). In multivariate
analysis, the rate of relapse/progression was similar between
the UCB and the MisMUD groups (HR, .62; 95% CI, .37 to 1.03;
P¼ .07), but it was signiﬁcantly lower in the MUD group than
in the UCB group (HR, .60; 95% CI, .39 to .92; P ¼ .02).
Furthermore, the rate of relapse/progression was signiﬁ-
cantly increased in patients in relapse/progression at trans-
plantation and in those with intermediate or high-risk
cytogenetic.
The Kaplan-Meier estimate of PFS at 2 years was 42.0%
(95% CI, 35.2% to 48.7%) in the UCB group versus 49.5% (95%
CI, 39.3% to 58.9%) in the MisMUD group (P ¼ .53) and 54.0%
(95% CI, 48.6% to 59.1%) in the MUD group (P ¼ .001)
(Figure 3C). In multivariable analysis, there was no signiﬁ-
cant difference in PFS between the UCB group and either the
MisMUD (HR, 1.17; 95% CI, .86 to 1.65; P ¼ .92) and the MUD
groups (HR, 1.10; 95% CI, .84 to 1.42; P ¼ .49). Similar to the
cumulative incidence of relapse/progression, PFS was
signiﬁcantly decreased in patients in relapse/progression at
transplantation and in those with intermediate or high-risk
cytogenetic. The 2-year OS was 47.9% (95% CI, 40.9% to
54.6%), 50.5% (95% CI, 40.3% to 59.8%), and 56.7% (95% CI,
51.2% to 61.8%) in the UCB, MisMUD, and MUD groups,
respectively (P ¼ .81 and P ¼ .007) (Figure 3D). In multivar-
iable analysis, there was no signiﬁcant difference in OS be-
tween UCB group and both MisMUD (HR, .98; 95% CI, .66 to
1.45; P ¼ .92) and MUD groups (HR, .74; 95% CI, .52 to 1.03;
P ¼ .08). In contrast, OS was signiﬁcantly decreased in pa-
tients who underwent transplantation in relapse/progres-
sion compared with patients who underwent
transplantation in CR (HR, 3.15; 95% CI, 2.40 to 4.14; P< .001)
and in patients over 40 years of age at time of transplantation
(HR, 1.35; 95% CI, 1.02 to 1.79; P ¼ .04).
DISCUSSION
The use of RIC and NMA regimens before allo-SCT has
widely expanded over the past decade, allowing patients
with AML and comorbidities or older age to beneﬁt from a
potential immune graft-versus-leukemia effect. The primary
objective of this retrospective studywas to assess the relative
efﬁcacy of UCB compared with HLA-matched and 9/10
Figure 2. Outcome after allo-SCT of the MUD (green line), the MisMUD (blue line) and the UCB groups (red line). (A) Shows cumulative incidence of grade III and IV
acute GVHD, and (B) shows cumulative incidence of extensive chronic GVHD.
F. Malard et al. / Biol Blood Marrow Transplant 21 (2015) 1059e10671064mismatched unrelated donor PBSC in adults with AML
treated with RIC or NMA conditioning regimens.
In this study, with a median follow-up of more than 3.5
years, UCB and 9/10 HLA MUD PBSC appear to be suitable
alternative stem cell sources when there is no 10/10 HLA
MUD PBSC available: in multivariate analysis OS, PFS, and
NRMwere comparable between the 3 stem cells sources. The
ﬁnding of a comparable NRM between the 3 stem cells
sources is 1 of the most interesting discoveries of our study.
Indeed, patients eligible to RIC/NMA allo-SCT are frequently
elderly, heavily pretreated, or impaired by comorbidities, and
most physicians hesitate to use UCB to perform RIC/NMAFigure 3. Outcome after allo-SCT of the MUD (green line), the MisMUD (blue line)
mortality; (B) shows cumulative incidence of relapse; (C) shows progression-free surallo-SCT in them when there is no matched related or un-
related donor available. The main cause of NRM after UCB
transplantation is infectious complications [23-25], but in
our retrospective study, we were unable to analyze the
impact of infection-related NRM. The cumulative incidence
of grade III and IV aGVHD and cGVHD was lower in the UCB
group compared with the MisMUD. In contrast, despite only
PBSC being used in theMisMUD andMUD groups [26,27], the
cumulative incidence of extensive cGVHD was similar be-
tween UCB and both MisMUD and MUD. Nevertheless, the
frequent use of ATG in those groups, which has increasingly
proven to exert a protective effect against severe cGVHDand the UCB groups (red line). (A) Shows cumulative incidence of nonrelapse
vival; and (D) shows overall survival.
F. Malard et al. / Biol Blood Marrow Transplant 21 (2015) 1059e1067 1065[28-30], probably limited the higher rate of extensive cGVHD,
particularly in the MisMUD group.
Our results are comparable to those reported in ran-
domized studies evaluating ATG in MUD and MisMUD
allo-SCT. Finke et al. reported a cumulative incidence of
extensive cGVHD of 12.2% at 2 years in the ATG group,
comparable to our study, against 42.6% in the non-ATG group
[30]. Walker et al. reported an even lower cumulative inci-
dence of extensive cGVHD of 4.4% at 2 years in the ATG group,
against 431% in the non-ATG group [31]. The cumulative
incidence of neutrophil recovery was signiﬁcantly lower af-
ter UCB transplantation, consistent with most previous re-
ports [6,7,32].
In AML, the main cause of treatment failure after RIC/
NMA allo-SCT is leukemia progression or relapse. The cu-
mulative incidence of relapse/progression was signiﬁcantly
increased with UCB compared with MUD, including in
multivariate analysis. The incidence in our UCB group (39.6%
at 2 years [95% CI, 36.2% to 43.0%]) is similar to that reported
in a similar setting by Chen et al. [32] (42.7% at 2 years) or
Brunstein et al. (49% at 2 years) [6]. Furthermore, Peffault de
Latour et al. recently described an increased cumulative
incidence of relapse with UCB compared with sibling and
unrelated donors after RIC allo-SCT [33]. In our study, there
was a trend towards a larger number of patients with high-
risk cytogenetics in the UCB group and, in multivariate
analysis, high-risk cytogenetics was associated with a
signiﬁcantly increased risk of relapse/progression and a
worse PFS. Thus, the higher relapse/progression rate in the
UCB patients might be related to the over-representation of
high-risk cytogenetics in this group. As to disease status at
transplantation, we acknowledge that there is a trend to-
wards a lower number of patients with AML in relapse/pro-
gression at transplantation in the UCB group. However,
intensity of conditioning regimen is an important determi-
nant in AML control, particularly in the setting of progressive
disease at transplantation, and patients in the UCB group
received signiﬁcantly less cytotoxic regimen, with a majority
of NMA, TBI-based conditioning regimen, compared with the
MisMUD and MUD groups. The increased risk of relapse in
AML patients after NMA low-dose TBI-based conditioning
regimen has been previously reported [34], and our study
conﬁrmed such a trend (HR, 1.25; 95% CI, .81 to 1.75; P¼ .20).
The overall use of less cytotoxic conditioning regimen in the
UCB group, may have contributed to the increased cumula-
tive incidence of relapse/progression. These results highlight
the issue of AML control in the setting of RIC and NMA
conditioning regimen, making the development of new
conditioning regimens to increase cytotoxicity and improve
disease control without increasing NRM of paramount
importance. Thus, we recently reported that a reduced-
toxicity regimen based on Flu, ATG, and 3 days of busulfan
appeared to be safe, with a low NRM at 2 years (11%) in high-
risk patients, and efﬁcient for disease control [10]. Such
conditioning regimens should be developed not only for
matched related donors and unrelated donors, but also for
UCB and haploidentical family donors. Similarly, the devel-
opment of several strategies to reduce relapse after allo-SCT
is ongoing, such as hypomethylating agents alone [35] or in
combination with prophylactic delayed lymphocyte infusion
or target therapy with FLT3 inhibitors for FLT3-positive AML
[36,37].
Recent studies demonstrated that the UCB trans-
plantation outcomes could be improved when matching at
the HLA-C locus is considered [38] and when HLA typing isperformed at the allele level for HLA-A, -B, and -C [39,40]. At
this level, mismatch at 1 or 2 alleles was better tolerated,
with an improved neutrophil recovery and a decreased NRM
[39]. In our study for UCB selection, HLA typing was per-
formed at the antigen level for HLA-A and -B and at the allele
level for HLA-DRB1, and data were not available to retro-
spectively evaluate the impact of high-resolution HLA class I
matching on the outcome after UCB allo-SCT. It seems likely
that, in comparison to other alternative donors, further
improvement of the UCB allo-SCT outcome can be achieved
when class I HLA-matching is performed at the allele level.
It would be very interesting to analyze the impact of the
type of mismatch in the MisMUD group. Although it is well
established that a single HLA mismatch, even at the allele
level, has a signiﬁcant impact on patients’ outcome [41], the
inﬂuence of each HLA locus mismatch is variable. Previous
reports suggested that mismatches at HLA-B or -C allele level
were better tolerated than those at HLA-A or -DRB1 [41]. In
daily practice, HLA-DRB1 mismatches are avoided and no
patient in our study received a transplant mismatch at the
HLA-DRB1 level. However, the type of HLA-A, -B, -C, and
-DQB1mismatch was very disparate and, unfortunately, the
number of patients in the MisMUD group was too small to
allow us to analyze the impact of type of allelic mismatch.
Besides UCB and MisMUD, a third alternative donor has
recently emerged: a haploidentical family donor [42]. The
results are very promising, especially when GVHD prophy-
laxis included the use of post-transplantation Cy [42].
Brunstein at al. reported a similar outcome for lymphoma
and leukemia patients after UCB allo-SCT and haploidentical
allo-SCT with post-transplantation Cy in the setting of RIC/
NMA [43]. Therefore, comparative studies restricted to AML
are necessary before drawing deﬁnitive conclusion. Given
the novelty of this option, haploidentical allo-SCT was not
routinely used in the Société Française de Greffe de Moelle et
de Therapie Cellulaire center during the study period (2002
to 2010), and could not be included in the current analysis.
In conclusion, our results suggest that UCB is a valid
alternative to the use of PBSC single allele mismatched un-
related donor in the setting of RIC/NMA and compared
favorably with PBSC 10/10 MUD. One must acknowledge that
UCB is an expensive alternative, but it has the advantage of
being readily available compared to sources from living do-
nors. Thus, the cost must be weighed carefully relative to the
urgency of the transplantation. No prospective comparative
study has been performed so far, given the difﬁculty of
including enough patients to be able to draw conclusions.
Therefore, international prospective comparative studies
evaluating alternative donors with HLA-A, -B, and -C typing
performed at the allele level for UCB selection are warranted.
These studies should also include haploidentical donors and,
for 9/10 HLA MisMUD, mismatches should be restricted to
those better tolerated (HLA-B and -C at the allele level). Only
such restrictive approaches would allow us to draw deﬁni-
tive conclusions regarding the best alternative donors for
AML patients.
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